PLIANT THERAPEUTICS, INC. Interest Expense Nonoperating
PLIANT THERAPEUTICS, INC. (PLRX) reported Interest Expense Nonoperating of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- PLIANT THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PLIANT THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $136.00K, a 83.69% decline year-over-year.
- PLIANT THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $815.00K, a 7.07% decline year-over-year.
- PLIANT THERAPEUTICS, INC. interest expense nonoperating for fiscal 2025 was $2.56M, a 15.38% decline from fiscal 2024.
- PLIANT THERAPEUTICS, INC. interest expense nonoperating for fiscal 2024 was $3.02M, a 138.67% increase from fiscal 2023.
- PLIANT THERAPEUTICS, INC. interest expense nonoperating for fiscal 2023 was $1.27M, a 60.18% increase from fiscal 2022.
- PLIANT THERAPEUTICS, INC. interest expense nonoperating for fiscal 2022 was $791.00K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $136.00K derived: sum of 3 quarters · filed 2026-08-11 | $951.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 | $136.00K derived: sum of 2 quarters · filed 2026-05-11 | $951.00K derived: sum of 3 quarters · filed 2026-05-11 | $1.76M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $136.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $951.00K derived: sum of 2 quarters · filed 2026-03-11 | $1.76M derived: sum of 3 quarters · filed 2026-08-11 | $2.56M 10-K · filed 2026-03-11 |
| 2025-09-30 | $815.00K 10-Q · filed 2025-11-06 | $1.62M derived: sum of 2 quarters · filed 2026-08-11 | $2.42M 10-Q · filed 2025-11-06 | $3.26M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $809.00K 10-Q · filed 2026-08-11 | $1.61M 10-Q · filed 2026-08-11 | $2.44M derived: sum of 3 quarters · filed 2026-08-11 | $3.32M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $799.00K 10-Q · filed 2026-05-11 | $1.63M derived: sum of 2 quarters · filed 2026-05-11 | $2.51M derived: sum of 3 quarters · filed 2026-05-11 | $3.38M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $834.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $1.71M derived: sum of 2 quarters · filed 2026-03-11 | $2.58M derived: sum of 3 quarters · filed 2026-03-11 | $3.02M 10-K · filed 2026-03-11 |
| 2024-09-30 | $877.00K 10-Q · filed 2025-11-06 | $1.75M derived: sum of 2 quarters · filed 2025-11-06 | $2.19M 10-Q · filed 2025-11-06 | $2.51M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $868.00K 10-Q · filed 2025-08-07 | $1.31M 10-Q · filed 2025-08-07 | $1.63M derived: sum of 3 quarters · filed 2025-08-07 | $1.95M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $445.00K 10-Q · filed 2025-05-08 | $766.00K derived: sum of 2 quarters · filed 2025-05-08 | $1.08M derived: sum of 3 quarters · filed 2025-05-08 | $1.40M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $321.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $638.00K derived: sum of 2 quarters · filed 2025-03-03 | $957.00K derived: sum of 3 quarters · filed 2025-03-03 | $1.27M 10-K · filed 2025-03-03 |
| 2023-09-30 | $317.00K 10-Q · filed 2024-11-07 | $636.00K derived: sum of 2 quarters · filed 2024-11-07 | $946.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $319.00K 10-Q · filed 2024-08-07 | $630.00K 10-Q · filed 2024-08-07 | ||
| 2022-12-31 | $791.00K 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |